- Home
- BKU vs MLYS Comparison
BKU vs MLYS Comparison
Compare BKU & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- MLYS
- Stock Information
- Founded
- BKU 2009
- MLYS 2019
- Country
- BKU United States
- MLYS United States
- Employees
- BKU N/A
- MLYS N/A
- Industry
- BKU Savings Institutions
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- MLYS Health Care
- Exchange
- BKU Nasdaq
- MLYS Nasdaq
- Market Cap
- BKU 2.9B
- MLYS 3.1B
- IPO Year
- BKU 2011
- MLYS 2023
- Fundamental
- Price
- BKU $39.70
- MLYS $37.06
- Analyst Decision
- BKU Hold
- MLYS Strong Buy
- Analyst Count
- BKU 11
- MLYS 6
- Target Price
- BKU $41.82
- MLYS $42.60
- AVG Volume (30 Days)
- BKU 911.1K
- MLYS 1.5M
- Earning Date
- BKU 10-22-2025
- MLYS 11-10-2025
- Dividend Yield
- BKU 3.12%
- MLYS N/A
- EPS Growth
- BKU 51.05
- MLYS N/A
- EPS
- BKU 3.41
- MLYS N/A
- Revenue
- BKU $999,760,000.00
- MLYS N/A
- Revenue This Year
- BKU $15.41
- MLYS N/A
- Revenue Next Year
- BKU $6.24
- MLYS N/A
- P/E Ratio
- BKU $11.65
- MLYS N/A
- Revenue Growth
- BKU 13.39
- MLYS N/A
- 52 Week Low
- BKU $28.21
- MLYS $8.24
- 52 Week High
- BKU $44.45
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- BKU 60.71
- MLYS 62.03
- Support Level
- BKU $37.36
- MLYS $37.48
- Resistance Level
- BKU $40.40
- MLYS $40.91
- Average True Range (ATR)
- BKU 0.99
- MLYS 2.15
- MACD
- BKU 0.04
- MLYS -0.90
- Stochastic Oscillator
- BKU 71.17
- MLYS 25.89
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.